Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259818
Status:
COMPLETED
Last Update Posted:
2008-01-24
First Post:
2005-11-30
Brief Title:
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors
Sponsor:
Erimos Pharmaceuticals
Organization:
Erimos Pharmaceuticals
Study Overview
Official Title:
An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid EM-1421 in Subjects With Refractory Malignant Tumors
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I dose escalation study of EM-1421 administered by intravenous infusion IV for five consecutive days every 28 days to patients with solid tumors refractory to current therapies There have been no previous human studies of intravenous into ones vein EM-1421 treatment however lab research research in test tubes andor animals suggests that EM-1421 has shown some activity against tumors in animals This activity in animal models suggests that EM-1421 may be a useful chemotherapy for human cancer
The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion The efficacy of the treatment will also be measured
The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion The efficacy of the treatment will also be measured
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None